We first tested our method on the set of 590 breast cancer TCGA samples that were either prescribed aromatase inhibitors, or were not considered for this type of treatment given their ER status, for which we assigned artificial “non-response” labels (see Materials and methods, Classification). This evidence concerns the gene ESR1 and breast carcinoma.